One-Study Path to FDA Drug Approvals Sparks Policy Debate
FDA Commissioner Marty Makary and Prasad argue that a single pivotal study could suffice for drug approvals, a shift aimed at speeding access but drawing concerns about the robustness of evidence and patient safety.
